ubiquinone and Conjunctival-Diseases

A prospective, open-label study in 20 professional swimmers evaluated the efficacy and safety of an ophthalmic solution containing crosslinked hyaluronic acid, coenzyme Q10, and vitamin E TPGS in releasing eye irritation and restoring ocular surface damages after prolonged exposure to chlorinated water.. Individually, one eye was instilled with the ophthalmic solution and the other used as a comparator. Eye drops were self-administered three times a day for 2 months. Tear film breakup time (primary endpoint), Schirmer I test, beating of eyelashes/min, tear osmolarity, corneal and conjunctival staining with fluorescein, Ocular Surface Disease Index questionnaire, subject satisfaction, visual acuity (secondary endpoints), and Efron Grading Scale were evaluated at screening/baseline (V1), week 1 (V2), week 2 (V3), week 4 (V4), and week 8 (V5).. After 2 months, breakup time test significantly improved in the treated eyes (+1.67 s) compared to control (-3.00 s) (. The adequate combination of crosslinked hyaluronic acid, coenzyme Q10, and vitamin E TPGS, contained in the ophthalmic solution VisuXL

Topics: Administration, Ophthalmic; Adolescent; Adult; Chloramines; Conjunctival Diseases; Corneal Diseases; Cross-Linking Reagents; Disinfectants; Drug Combinations; Humans; Hyaluronic Acid; Hyperemia; Male; Ophthalmic Solutions; Osmolar Concentration; Prospective Studies; Quality of Life; Surveys and Questionnaires; Swimming Pools; Tears; Ubiquinone; Vitamin E; Vitamins; Water Pollutants, Chemical; Young Adult